H.C. Wainwright analyst Mitchell Kapoor reiterated a Buy rating on Rallybio (RLYB – Research Report) today and set a price target of $5.00.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Mitchell Kapoor has given his Buy rating due to a combination of factors including Rallybio’s progress in the development of its key therapeutic candidates. The dosing of the first pregnant subject in the FNAIT study is seen as a significant milestone, as it indicates potential progress towards addressing a rare immune disorder for which there is currently no FDA-approved therapy. This advancement suggests the possibility of RLYB212 becoming a standard-of-care treatment for FNAIT prevention.
Furthermore, there are several anticipated catalysts in 2025 that could drive Rallybio’s valuation higher. These include interim data releases and clinical study initiations for RLYB212, RLYB116, and REV102. Kapoor’s analysis incorporates a discounted cash flow approach, leading to a 12-month price target of $5 per share, based on the promising prospects for RLYB212 and a moderate probability of success for other pipeline candidates. Despite some risks, including clinical trial delays and partnership challenges, the potential rewards justify the Buy rating.
In another report released yesterday, JMP Securities also reiterated a Buy rating on the stock with a $7.00 price target.